This article provides an overview of the regulation of medical devices and drugs in the European Union and the US. It is important for all stakeholders involved in bringing a medical device or drugs to market to have an understanding of the regulatory requirements involved in this process. This article demonstrates that the regulation of these products is an extremely complex process.
Introduction
The medical device and drug regulatory frameworks are extremely complex, which can significantly delay manufacturers attempting to bring new devices and drugs i to the international market. Such delays can result in patients not receiving timely benefits from technological breakthroughs. An understanding of these regulations is critical for all stakeholders in order to avoid or minimize these delays.
Regulation of Medical Devices in the EU
The regulation of medical devices in the European Union (EU) is relevantly recent in comparison to the US. The regulation of medical devices in the EU began in the mid-1990s, whereas it began in the US in the mid-1930s. In the EU prior to the mid-1990s, each country had its own legislation, and subsequently, the approval process was different in each country. Today, medical devices in the EU are regulated by 3 directives: 3 This is known as the in vitro diagnostic directive (IVD directive).
The European Community's definition for medical devices can be found in the Medical Devices Directive 93/42/EEC. 1 Medical devices are defined in the EU as any instrument, appliance, apparatus, material or other article, whether used alone or in combination, including the software necessary for its proper application, intended by the manufacturer to be used for human beings for the purpose of: diagnosis, prevention, monitoring, treatment or alleviation of disease; diagnosis, monitoring, alleviation of or compensation for an injury or handicap; investigation, replacement or modification of the anatomy or of physiological process; control of conception; and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means. 1 Medical devices vary greatly in complexity and application. They can range from simple bandages and medical thermometers to advanced devices such as magnetic resonance imaging machines and x-ray machines. The classes of devices are class I, class IIa, class IIb, and class III. The classes are based upon contact time, invasiveness, and whether active or not. The classification system is a risk-based system in which the vulnerability of the human body takes account of the potential risks associated with the devices. This system allows the use of a set of criteria that can be combined in various ways in order to determine the classification of a variety of medical devices. In such a system, the level of control relates to the level of potential hazards inherent in the type of device concerned. Table 1 shows the different classifications, the corresponding risk levels, and examples of devices in each class.
In contrast to the US regulatory system in which there is 1 principal regulatory body, the Food and Drug Administration (FDA) that oversees the medical device system in a centralized manner, in the EU, there is a multifaceted system with roles for a number of authorities including private entities. There are 5 authorities involved with the regulation of medical devices in the EU:
1. the European Commission, 2. competent authorities, 3. notified bodies, 4. authorized representatives, and 5. manufacturers.
European Commission
The European Commission is the EU's executive body and is responsible for proposing legislation and implementing decisions and for the general day-to-day running of the union. The department responsible for medical devices and drugs is the Directorate-General for Health and Consumers.
Competent Authorities
A competent authority is a body with authority to act on behalf of the government of a member state to ensure that the requirements of the medical devices directives are transposed into national law and are applied. The government of each member state is required to appoint a competent authority responsible for medical devices. The competent authority reports to the minister of health of the member state. Responsibilities of the competent authorities include the appointment of notified bodies, overseeing of the work of the notified bodies, surveillance of medical devices on sale in their own member state, and assessment of adverse incidents.
Notified Bodies
Notified bodies are certification organizations. Their role is in assessing manufacturers' compliance with the requirements of European medical devices law, signifying compliance by granting certificates and monitoring it through regular audits. The scope of a notified body's role depends on the class of the product. In the case of a class III device, for instance, a notified body will examine the product design and audit the quality system. A notified body will not get involved with a class I device unless it is sold sterile and/or has a measuring function, and then, its scrutiny is limited to those aspects. Notified bodies are privately held, for-profit organizations. Competent authorities of member states subcontract notified bodies, which perform the certification of goods on the member state's behalf. In other words, in contrast with the US approach, manufacturers are not obliged to undergo governmental review in order to get access to the market in Europe.
The European Commission, competent authorities, and notified bodies, when combined together, are more or less comparable to the function of the FDA. The notified body is roughly equivalent to the FDA's inspection branch. Notified bodies, however, do not have any enforcement powers that the inspection branch has.
Authorized Representatives
An ''authorised representative means any natural or legal person established in the Community who, explicitly designated by the manufacturer, acts and may be addressed by authorities and bodies in the Community instead of the manufacture with regard to the latter's obligations under this Directive.'' 3 An authorized representative cannot fully assume the regulatory responsibilities of the manufacturer because that would imply it has powers of inspection and coercion that the manufacturer would never tolerate. The authorized representative must have sufficient regulatory expertise to be able to act on behalf of the manufacturer in compliance matters when so requested. As the law stands today, there are no restrictions as to who can be an authorized representative. No authorization is needed, and no qualifications are required. Manufacturer A manufacturer or the person placing the product on the market is defined as ''the natural or legal person with responsibility for the design, manufacturer, packaging and labelling of a device before it is placed on the market under his own name, regardless of whether these operations are carried out by that person himself or on his behalf by a third party.'' 1 This definition permits all actual manufacturing operations to be delegated to a third party as long as the ''legal manufacturer'' retains responsibility and places the products on the market under its own name. This implies that distribution companies that sell thirdparty manufactured products under their own name may very well be considered legal manufacturers. It is important to understand that despite the possibility of being able to delegate virtually all manufacturing tasks, the legal manufacturer is ultimately responsible for any noncompliance, even if it rises from the actions or failings of a subcontractor.
Medical Device Pathway to Market in the EU
In order to commercialize medical devices in the EU, manufacturers must obtain CE marking certification and affix the CE marking as part of their device registration efforts. CE is an abbreviation for the French ''Conformité Européenne,'' meaning ''European Conformity.'' This mark is not a guarantee of safety. It signifies that the manufacturer claims that it has complied with the relevant ''essential requirements'' in the directives and that the device is fit for its intended purpose. It also signifies that the product can be freely marketed anywhere in the EU without further control. The ''essential requirements'' in the Medical Devices Directive 93/42/EEC can be divided into 2 groups: the first refers to a set of general requirements for safety and performance that applies to all devices. The second is a list of specific and technical requirements regarding design and manufacturing that may or may not apply, depending on the nature of the device. Manufacturers have to demonstrate and document compliance with the regulations and issue a declaration of conformity. In certain situations, such as class I sterile devices, it may require the involvement of a notified body. Class III devices require clinical studies, barring when data already exist.
In the case of devices for clinical investigation and those that are custom made, the CE mark is not mandatory. The manufacturer has to follow Annex VIII of the Medical Devices Directive 93/42/EEC regarding the Statement Concerning Devices for Special Purposes 1 and declare that its products conform to the ''essential requirements.'' Clinical data are intended to demonstrate the device's safety and that it performs as intended by the manufacturer. In this context, the expression has a broad meaning and includes everything from bench testing to clinical trials in humans. Data can be compiled from the literature or result from specifically designed clinical investigations. If the latter path is chosen, manufacturers must abide by the standard International Organization for Standardization 14155, 4 and the clinical trials must be preapproved by a competent authority.
Regulation of Medical Devices in the US
Regulation of medical devices in the US began in 1938 and reflected the relatively simple technological devices then on the market. In 1938, the Federal Food, Drug, and Cosmetic Act was passed; the act gave the FDA multiple responsibilities and authorities for drugs and medical devices, including designating adulterated or misbranded products as violating the law, as well as the authority to seize adulterated or misbranded medical devices. Shortcomings of the drug and device regulatory structure were becoming evident as more drugs and devices came on the market. There was an increasing need for premarket review of devices rather than just enforcement by seizure of problematic devices. The first step in addressing these problems came with the passage of the Drug Amendments of 1962. It was also becoming clear that devices should be treated differently from drugs and that no single form of regulation would be appropriate for all medical devices. The resultant Medical Device Amendments of 1976 mandated testing and FDA approval of medical devices. Most of the regulations for medical devices can be found in the Code of Federal Regulations (21 CFR 800-1299) 5 and are enforced by the FDA.
The US definition for medical devices can be found in the Code of Federal Regulations (21 CFR) of the Federal Food, Drug, and Cosmetic Act. 6 In the act, devices are defined as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is: recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and that does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and that is not dependent upon being metabolized for the achievement of any of its primary intended purposes. 6 The Medical Device Amendments gave rise to 3 classes of medical devices. Each class required a distinct regulation level for safety and effectiveness. In the US, the classification system for medical devices is based on the level of risk to the patient, the intended use, and the indication for use. There are 3 classes of devices: class I, II, and III (regulatory control increases from class I to class III). Class I devices are defined as non-life sustaining. These products are the least complicated, and their failure poses little risk. Class II devices are more complicated and present more risks than class I, although they are non-life sustaining. These may be subject to specific performance standards. Class III devices sustain or support life, so that their failure is life threatening. These products are subject to specific performance standards. Table 2 shows the different classifications, the corresponding risk levels, and examples of devices in each class.
Class I is the lowest level with the least amount of regulatory control due to the low level of risk to the patient. These devices are subject to ''general controls,'' which include ''establishment registration'' by the manufacturers, distributors, repackagers, and relabelers; listing in the FDA database; Good Manufacturing Practices; labeling of the medical device; and a 510(k) premarket notification. The majority of class I devices are exempt from premarket notification and Good Manufacturing Practices.
Class II medical devices have more risks than a class I device and require a higher level of regulatory control. In addition to ''general controls,'' they are also subject to ''special controls.'' ''Special controls'' include additional labeling requirements, mandatory performance standards, and postmarket surveillance. Some class II devices are exempt from premarket notification; however, they are subject to limitations if they present a new intended use or question new issues of safety and effectiveness.
Class III medical devices represent the highest risk level and require the most rigorous review and regulatory oversight. The majority of class III devices require FDA approval of a premarket approval application (PMA). Approval of the PMA normally requires clinical data demonstrating reasonable assurance that the device is safe and effective in the target population. Class III medical devices are used to support or sustain life, prevent impairment, or present a potential for an increased risk of illness or injury to the user. In addition to the level of risk, other devices may be included in the class III category such as if the device is found to be not ''substantially equivalent'' (did not meet the requirement for a 510(k)) or does not have a ''predicate'' (a device that has been cleared through a 510(k) review) to compare to for premarket review. A 510(k) submission is a premarket notification submitted to the FDA to demonstrate that the medical device to be marketed is as safe and effective or substantially equivalent to a legally marketed device. Devices that meet the requirements for the 510(k) are given the designation of ''cleared,'' and devices that undergo a class III review and meet the requirements are given the designation of ''approved.''
The FDA regulates the majority of medical devices through the Center for Devices and Radiological Health, whose main responsibility is to regulate manufacturers, repackagers, relabelers, developers of investigational medical devices, and importers of medical devices. 7 The FDA carries out its medical device responsibilities by assessing new products before they are marketed for conformance to the requisite design, engineering bench tests, acquiring data from animal trials or clinical trials in patients, and ensuring that quality systems are in place in the device manufacturing plants through inspection and enforcement activities. It also collects and monitors adverse effects from marketed products and investigations and takes actions to prevent injury or death.
Medical Device Pathway to Market in the US
In order to market a medical device, there are 4 options: exempt, 510(k), PMA, and the humanitarian device exemption (HDE). Clinical studies of investigational devices must comply with the FDA's investigational device exemption (IDE) regulations.
Most class I and some class II devices are exempt from the premarket notification 510(k) requirements. They still, however, have to comply with the ''general controls.'' They must be manufactured under a quality assurance program, be suitable for the intended use, be adequately packaged and properly labeled, and have establishment registration and device listing forms on file with the FDA.
The 510(k) process is a 90-day review procedure based on the view that the device to be marketed is at least as safe and effective, that is, ''substantially equivalent'' or predicate device, to one that was already approved by the FDA and is not subject to a PMA. Most class II devices follow this path. In addition to the premarket notification 510(k) and the ''general controls,'' devices must comply with ''special controls,'' namely, performance standards, guidance documents, or implementation of postmarket surveillance.
The PMA can be equated to the design dossier that is necessary to market European class III devices. It is the most comprehensive type of device marketing application. The process involves evaluating the safety and effectiveness of class III medical devices. Although FDA regulations provide 180 days to review the PMA and make a determination, the process can take between 6 months to 2 years. This depends on factors such as the report on clinical studies, the quality of documents, and the amount of time necessary for the manufacturers to respond to FDA concerns. Before the FDA Modernization Act of 1997, 8 if an innovative device was found ''not substantially equivalent'' (NSE), it was classified as class III, and a PMA was required, resulting in a conflict between the need for being innovative and a more complex commercialization process. Currently, the de novo process allows the reclassification of devices to class I or class II, providing a simpler route to market for novel low-risk devices. This process, which has to begin within 30 days of an NSE letter, has a review period of 60 days, and if the device is classified as class I or II, the applicant is given an approval order to market the device. However, if it is decided that the device must remain in the class III category, it cannot be marketed until the applicant has obtained an approved PMA.
The use of the de novo route is a strategic decision and depends upon the product. The choice of such a route is influenced by factors such as the device's market and other barriers to market entry. For example, if there is insignificant patent protection, manufacturers can benefit from a class III classification because it will represent to competitors a barrier to market entrance. The HDE is a specific path for class III medical devices designed to address diseases and conditions that affect fewer than 4000 patients in the US per year. This path aims to be an incentive for the development of devices for use in the treatment or diagnosis of diseases affecting small populations.
An investigational device is a medical device that is the subject of a human research study to evaluate its safety and/or effectiveness. A company developing an investigational medical device in the US can only conduct clinical studies of the device in the US if it obtains an IDE from the FDA.
Regulation of Drugs in the EU
A drug may be placed on the EU market only when a ''marketing authorization'' has been issued by the regulatory authority of a member state for its own territory or when an authorization is granted for the entire European Community. Drugs can be marketed in the EU only when data supporting their quality, safety, and efficacy have been assessed and marketing authorization granted.
Article 1(2) of European Council Directive 65/65/EEC defines a drug as follows:
Any substance or combination of substances presented for treating or preventing disease in human beings or animals.
Any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings or in animals is likewise considered a drug. 9 In the EU, drugs are covered by the internal market principle of the free movement of goods. Throughout much of the 20th century, in the absence of a harmonized EU legislative framework, individual member states enacted national legislation that regulated drugs for human use. With the adoption of European Council Directive 65/65/EEC of January 26, 1965, this stipulated that a drug may only be placed on the market in the EU after a ''marketing authorization'' has been granted. Since 1965, the EU pharmaceutical legislation framework has been extended and developed with the aim of protecting public health and preserving the free movement of drugs.
In 1995, a new system for authorizing drugs entered into law. It was based upon 2 separate European Community procedures for granting a ''marketing authorization'' for a drug: the centralized procedure and the mutual recognition procedure. The centralized procedure is administered through the European Medicines Agency (EMA), and competent authorities of member states are responsible for the mutual recognition procedure. In addition, a purely national authorization is possible for a product that is marketed in only 1 member state.
The new pharmaceutical regulations (Directive 2004/27/EC 10 ) that came into force in 2005 provided another option to authorize drugs within the EU: the decentralized procedure. The principal purpose of medical product regulation in the EU is to safeguard public health. This purpose is complicated by the fact that the EU is not a single nation but consists of multiple, independent countries, each with its own legislative framework and cultural, medical, and political practices. As part of the European Community, each member state is subject to relevant EU law.
In the EU, there are a number of institutional players that are involved with the regulation of drugs. The EMA is responsible for the scientific evaluation of medicines and consequently plays a pivotal role in the approval of pharmaceutical products in the EU. The EMA is analogous to the FDA. The EMA is not a law enforcement agency. Rather, the EMA is responsible for overseeing drugs authorized for use within the European Community and for maintaining relevant databases. It also coordinates pharmacovigilance. There is no corresponding institution for medical devices in the EU.
The European Commission is the executive body of the European Union. The European Commission Directorate General for Health and Consumers (SANCO) Pharmaceuticals Unit has responsibility for drug regulation. The European Commission also chairs both the Pharmaceutical and Standing Committees. The former is the pharmaceutical sector's policy-making unit; the latter is the European Commission's decision-making arm for refusing or granting authorization.
The Route to Market for EU Drugs
Regardless of the registration procedure employed, the ''marketing authorization'' is granted to a single party referred to as the marketing authorization holder (MAH). The MAH must be established within the European Economic Area. The ''marketing authorization'' permits the MAH to market the product in the applicable region and, in so doing, places a number of obligations upon the MAH. These include maintaining the ''marketing authorization'' to reflect technical and scientific progress, releasing the product onto the market in accordance with EU law (through a qualified person), and providing pharmacovigilance and scientific information.
Three marketing authorization routes are available in Europe (for products authorized in more than 1 member state): the mutual recognition procedure, the decentralized procedure, and the centralized procedure. In the mutual recognition procedure, which is applicable to the majority of conventional drugs, after data have been evaluated by the relevant member state's regulatory agency, the initial ''marketing authorization'' is recognized by other member states. The mutual recognition procedure, therefore, can result in multiple, identical ''marketing authorizations.'' The current legislation allows the mutual recognition procedure only for products that already have a ''marketing authorization.'' In the decentralized procedure, this is also applicable to the majority of conventional drugs. The evaluation is also performed by 1 national regulatory agency, but the ''marketing authorization'' is usually granted in other member states only after all member states involved reach agreement.
The centralized procedure is mandatory for human medicines derived from biotechnological processes, for the treatment of rare disorders (orphan drugs), and for drugs for human use that contain an active substance authorized in the European Community after May 20, 2004 and that are for the treatment of cancer, AIDS, diabetes, or neurodegenerative disorders. In the centralized procedure, the Committee for Drugs for Human Use (CHMP) evaluates a given drug's data at the European level. This process results in 1 European Community or European ''marketing authorization'' that is valid throughout all EU member states. The EMA administers the centralized procedure; however, the actual license takes the form of a decision issued by the European Commission.
Regulation of Drugs in the US
The birth of FDA guardianship and the origins of drug and medical product regulation began with a large medical calamity. 11 In 1937, over 100 people, mainly children, in the US died of diethylene glycol poisoning as a result of the use of a sulfanilamide elixir, which used the chemical as a solvent without any safety testing. 12 At that time, there were no required toxicity testing, scientific literature review, or animal experiments, and selling potentially toxic drugs was technically legal. In this case, product safety conflicted with another constraint: the desire for speedy market placement. This led to the introduction of the Federal Food, Drug, and Cosmetic Act in 1938.
The second calamity that led to the expansion of medicine regulation far more than any event in history was the thalidomide disaster in the EU. Thalidomide was a sedative and hypnotic that first went on sale in Germany in 1956. Between 1958 and 1960, it was introduced in 46 different countries worldwide, resulting in an estimated 10,000 babies being born with phocomelia. While this drug was not approved for sale in the US, the incident led the initiative for the FDA to regulate efficacy as well as safety for US-bound drugs.
The Federal Food, Drug, and Cosmetic Act defines drugs by their intended use as ''articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease'' and ''articles (other than food) intended to affect the structure or any function of the body of man or other animals'' (201(g)(1)). 6 In addition, the job of the FDA's Center for Drug Evaluation and Research is to evaluate new drugs before they can be sold and to ensure that drugs marketed in the US are safe and effective.
The Route to Market for US Drugs
In the US, the FDA requires the following sequence of events prior to approving a drug: preclinical testing, an investigational new drug (IND) application, phase I clinical trials, phase II clinical trials, phase III clinical trials, a new drug application (NDA), and phase IV studies.
During preclinical testing, a pharmaceutical company performs specific studies before the future drug is given to a human being. Laboratory and animal studies must be conducted to prove the biological activity of the drug against the targeted disease. The drug must also be evaluated for safety.
The pharmaceutical company submits an IND application with the FDA to begin testing the drug in people. The IND application becomes effective if the FDA does not reject it within 30 days. The IND application must include the following information: the results of previous experiments; how where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. The IND application must also be reviewed and approved by the institutional review board where the studies will be conducted.
Phase I clinical trial studies are usually the first tests of a drug under development in healthy volunteers. These studies involve about 20 to 80 volunteers. The tests determine a drug's safety profile, including the safe dosage range; how the drug is absorbed, distributed, metabolized, and excreted; and the duration of its action. Phase I trials take on average 1 year. 13 Phase II clinical trials are slightly larger studies that are conducted in patients with the disease for which the drug is intended. This phase is usually designed to identify the minimum and maximum dosages. The trials generally involve 100 to 300 volunteer patients and are controlled in design. They are performed to assess the drug's effectiveness. 13 Phase II typically takes about 2 years.
Phase III clinical trials are the definitive, large randomized trials that are submitted to the FDA in order to obtain approval of a drug. This phase examines the effectiveness as well as the safety of the new drug. Phase III trials usually involve 1000 to 3000 patients in clinics and hospitals. Patients are usually asked a list of possible side effects, often derived from what was observed in phase II studies. Patients are also free to report any other side effects that occur while they are on the new drug or the placebo. Phase III takes on average 3 years.
Following the phase III clinical trials, the drug manufacturer analyzes all the data from the studies and files an NDA with the FDA (provided the data appear to demonstrate the safety and effectiveness of the drug). The NDA contains all of the data gathered to date about the drug.
Phase IV is any organized collection of data from patients who are taking a drug that has already received approval from the FDA. In phase IV studies, patients may check boxes on a list (as in phase III studies), or they may just report other symptoms. Phase IV studies are commonly called ''postmarketing studies.'' Although there are other routes that can expedite the process, this is the usual journey for a drug from invention to market in the US.
Summary
This overview of medical device regulation demonstrated that it is a complex process. Part of the complexity can be attributed to the wide variety of items categorized as medical devices. Medical devices range from simple tools used during medical examinations such as tongue depressors and thermometers to high-technological, life-saving implants like heart valves and coronary stents. Another contributing factor to its complexity is that despite having largely similar regulations for medical devices, the EU and US have adopted different approaches to oversight. The US market is controlled though a centralized agency, the FDA, whereas the EU is much more decentralized, monitored by competent authority-appointed notified bodies that have no legal powers and that are commercial organizations who charge fees to the manufacturers.
Drug regulations are also complex. Differences in how the regions approach drug regulation also add complexity. In the US, once again, the FDA is responsible; in Europe, multiple agencies are involved: the EMA, CHMP, and national health agencies. A good illustration of how the 2 regions differ in approach is the registration process: in the US, there is 1 registration procedure; in Europe, there are 3: centralized, decentralized, and national.
The US and EU regulatory systems are under constant evaluation and scrutiny. They are an important element of any healthy, innovate medical technology ecosystem. They function as a tool for decreasing stakeholder uncertainty and ensuring public safety. Supportive regulations improve the investment climate in the industry by reducing related risks and, hence, promoting innovation in the short run and better and cheaper health care in the long run. In the regional context, therefore, regulation design can be a source of competitive advantage to a whole region in the international arena.
In conclusion, this article aims to provide an overview of the regulatory framework for medical devices and drugs in the EU and US, presenting the directives and federal laws that govern the approval of these products. This review has demonstrated that the regulation of these products is extremely complex, which confirms the views of other commenters. 14, 15 Each jurisdiction has its own regulatory framework with different legislation. Furthermore, there is a range of regulatory authorities involved, which adds to the complexity of the process.
Note i. For the purposes of this article, the term ''drug'' is used when referring to ''medicinal products'' in the EU and ''prescription drugs'' in the US.
